ALKS: Material agreement

Item 1.01 Entry into a Material Definitive Agreement. On November 6, 2026, Alkermes, Inc. and Alkermes Pharma Ireland Limited (together, “Alkermes”), two wholly-owned indirect subsidiaries of Alkermes plc (the “Company”), entered into a Confidential Settlement and License Agreement (the “Settlement Agreement”) with Teva Pharmaceuticals, Inc. (“Teva”, and together with Alkermes, the “parties”), resolving a patent infringement lawsuit relating to all dosage strengths of the Company’s product LYBALVI ® (olanzapine and samidorphan). The lawsuit was brought by Alkermes against Teva in the U.S. District Court for the District of New Jersey for infringement by Teva’s abbreviated new drug application (“ANDA”) No. 220379 of certain of the Company’s Orange Book-listed United States Patents for LYBALVI. Pursuant to the Settlement Agreement, Alkermes will grant Teva a non-exclusive, royalty-free, non-transferable, non-sublicensable limited license to make, have made, use, import, sell and offer for sale Teva’s products made under ANDA No. 220379 in the United States beginning on November 12, 2039, or, if Alkermes obtains pediatric exclusivity, on May 12, 2040, or earlier under certain circumstances. On November 9, 2026, the parties filed a joint Stipulation of Dismissal with Prejudice to dismiss the pending legal proceedings. The Settlement Agreement is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice. The foregoing description of certain provisions of the Settlement Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Settlement Agreement, which the Company intends to file as an exhibit to its Annual Report on Form 10-K for the year ending December 31, 2026. 2 SIGNA TURE Pursuant to